MedTrace Logo

Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma

NCT02481934 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2021-08-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine wether activated and expanded autologous Natural Killer cells (NKAEs) are effective in the treatment of patients with multiple myeloma on second or later relapse. NKAEs are used in combination with anti-myeloma drugs such as lenalidomide or bortezomib.

Conditions

Interventions

PROCEDURE

NKAE cells infusion

Expanded and activated autologous NK cells infusion. Each patient will receive two infusions of 7.5 x 106 expanded and activated autologous NK cells/kg/cycle.

DRUG

Lenalidomide

Lenalidomide, 10 mg oral/day during 21 days (cycle). Patients will receive 4 cycles.

DRUG

Bortezomib

Bortezomib, 1.3 mg/m2, s.c., days 1, 4, 8 and 11/cycle. Patients will receive 4 cycles.

Sponsors & Collaborators

  • Hospital Infantil Universitario Niño Jesús, Madrid, Spain

    collaborator OTHER

  • Joaquín Martínez López, MD, PhD

    lead OTHER

Principal Investigators

  • Joaquín Martínez López, M.D, Ph.D · Hospital Universitario 12 de Octubre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2016-07-31
Completion
2016-10-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02481934 on ClinicalTrials.gov